Meeting
2023 ASCO Annual Meeting
Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma.
Authors
Shogo Takei
Department of gastroenterology and gastrointestinal oncology, National Cancer Center Hospital East, Kashiwa, Japan
Shogo Takei , Daisuke Kotani , Kazuma Sato , Naoto Fujiwara , Akihito Kawazoe , Shruti Sharma , Erik Spickard , Punashi Dutta , Minetta C. Liu , Adham A Jurdi , Kohei Shitara , Takashi Kojima , Takeo Fujita
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Clinical Trial Registration Number
UMIN000042003
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3041)
DOI
10.1200/JCO.2023.41.16_suppl.3041
Abstract #
3041
Poster Bd #
239
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Circulating tumor DNA analysis in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy followed by surgery.
First Author: Mian Xie
Poster
2023 ASCO Annual Meeting
Associations among anesthesia-induced brain biomarkers during surgery, preoperative exposure to cancer therapeutics, and clinical outcomes.
First Author: Tom A.D. Stone
Poster
2018 ASCO Annual Meeting
Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach.
First Author: Lifeng Yang
Poster
2024 ASCO Breakthrough
Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer.
First Author: Vincent T. Ma